180 Life Sciences Corporate Media Kit

10 Clinical Stage Lead Program: Fibrosis & Anti-TNF Targeting common diseases - facilitates trials and potential sales Clinical trials supported by Prof Sallie Lamb, UK Developing targeted therapies for: • Early Stage Dupuytren’s disease (DD) - patent issued; Phase 2b/3 results expected Q4 2021 (1) • Frozen shoulder - patent issued; clinical trials projected in Q3 2021 • Post operative cognitive decline (POCD) - patent issued, clinical trials projected in Q4 2021 • Liver fibrosis (NASH) - initial laboratory studies done with Celgene-BMS on human tissue; preclinical studies started Q2 2020 (1) Approval only from MHRA/CCMO and relevant accredited ethics committees. Dupuytren’s Disease Frozen Shoulder Nash POCD Program led by Profs Jagdeep Nanchahal & Sir Marc Feldmann, Oxford, and Dr Glenn Larsen, USA 180 Life Sciences Corp. www.180lifesciences.com Q4 2020